News

Pfizer announces a first-line combination Rx for advanced RCC.

Posted on 5.21.2019

 

NOW APPROVED
new, first-line immunotherapy (IO) and tyrosine kinase inhibitor (TKI) combination for patients with advanced renal cell carcinoma (RCC)
Learn more ›
Read More

CMS finalizes rule which forces drug manufacturers to provide the list price for their products in direct-to-consumer ads.

Posted on 5.15.2019

The new policy is aimed at increasing transparency and vehemently opposed by industry. The new policy will apply to drugs or biologics with list prices greater than $35 for a month’s supply or the normal course of therapy, which HHS … Read More

Merck announces new FDA approval for KEYTRUDA

Posted on 5.3.2019

Merck announces new FDA approval for KEYTRUDA

Merck is pleased to announce that KEYTRUDA, in combination with axitinib, has been approved by the FDA for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

  • PD-L1 diagnostic testing is
Read More

AstraZeneca announces new CMS J-code assigned for IMFINZI®

Posted on 2.19.2019

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after January 1, 2019, J-Code J9173 can be … Read More

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients With Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)

Posted on 1.8.2019

Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. This indication is approved under accelerated approval based on tumor response rate Read More

AstraZeneca announces that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code.

Posted on 1.8.2019

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after January 1, 2019, the following code can … Read More

Astellas Pharma announces FDA approval of XOSPATA.

Posted on 11.30.2018

Astellas Pharma US, Inc. is pleased to announce that the FDA has approved XOSPATA. XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation … Read More

(FDA) approves a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.

Posted on 11.19.2018

On November 16, 2018, the U.S. Food and Drug Administration (FDA) approved a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.

The new indication is as follows:

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma
Read More

IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Posted on 11.16.2018

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after January 1, 2019, the following code can … Read More

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult Patients With Hepatocellular Carcinoma (HCC)

Posted on 11.16.2018
Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of patients with HCC who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and
Read More